BULERIA. Repositorio Institucional de la Universidad de León
Publicación
Artículo científico antes de ser publicado, versión del autor (Preprint)
Tissue plasminogen activator (tPA) of paternal origin is necessary for the success of in vitro but not of in vivo fertilisation in the mouse
[EN] Besides its fibrinolytic function, the plasminogen-plasmin (PLG-PLA) system is also involved in fertilisation, where plasminogen activators bind to plasminogen to produce plasmin, which modulates sperm binding to the zona pellucida. However, controversy exists, depending on the species, concerning the role of the different components of the system. This study focused its attention on the role of the PLG-PLA system on fertilisation in the mouse with special attention to tissue plasminogen activator (tPA). The presence of exogenous plasminogen reduced in vitro fertilisation (IVF) rates and this decline was attenuated by the presence of plasmin inhibitors in combination with plasminogen. The incubation of spermatozoa with either oocytes or cumulus cells together with plasminogen did not change the acrosome reaction but reduced the number of spermatozoa attached. When spermatozoa from tPA mice were used, the IVF rate decreased drastically, although the addition of exogenous tPA during gamete co-incubation under in vitro conditions increased fertilisation success. Moreover, fertility could not be restored after in vivo insemination of tPA spermatozoa in the female ampulla, although tPA males were able to fertilise in vivo. This study suggests a regulatory role of the PLG-PLA system during fertilisation in the mouse with possible implications in human reproduction clinics, such as failures in tPA production, which could be partially resolved by the addition of exogenous tPA during IVF treatment, SI, This work was supported by the Spanish Ministry of Economy and Competitiveness 519 (MINECO) and the European Regional Development Fund (FEDER), Grants AGL2012-520 40180-C03-01, AGL2015-66341-R, AGL2015-66145-R and AGL2015-70159-P, and 521 Fundación Séneca 20040/GERM/16. F.A.G.V. was supported by Jiménez de la 522 Espada mobility program-Fundación Séneca 2015 (19935/EE/15). This study was 523 also supported by Eunice Kennedy Shriver National Institute of Child Health and 524 Human Development NIH (RO1 HD38082) to P.E.V.